First-in-human Results of the Novel Transcatheter Mitral Valve Repair System for Severe Mitral Regurgitation  

作　　者：Zhi-Nan Lu Yutong Ke Yingnan Bian Jing He Wenhui Wu Xinmin Liu Yang Li Ran Liu Taiyang Luo Xunan Guo Guangyuan Song 

机构地区：[1]Interventional Center of vavular Heart Disease,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China [2]Echocardiography Department,Bejing Anzhen Hospital,Capital Medical University,Beijing 100029,China [3]Research and Development Department,Enlight Medical,Shanghai 201209,China

出　　处：《Cardiology Discovery》2024年第2期148-159,共12页心血管病探索（英文）

基　　金：This study is part of the China Degenerative Valve Disease II Cohort Study(China-DVD2 Study,NCT05044338);which is supported by the National Key R&D Program of China(2020YFC200801100).

摘　　要：Objective:To evaluate the feasibility,safety,and effectiveness of a novel edge-to-edge mitral valve repair system(the NovoClasp system)in patients with severe mitral regurgitation.Methods:In this prospective,single-arm,first-in-human study conducted at Beijing Anzhen Hospital,data were collected from patients undergoing transcatheter edge-to-edge repair using the NovoClasp system.The study candidates were patients exhibiting a mitral regurgitation severity of 3+or more and were at high-risk or contraindicated for surgical intervention.Technical success and device success according to the Mitral Valve Academic Research Consortium definitions were used as primary outcomes.Other safety and efficacy outcomes were prospectively assessed at device implantation,discharge,and 30 d,6 months,and 12 months post-procedure.Results:Between October 1,2021,and January 31,2022,11 patients were treated for moderate-to-severe(grade 3+)or severe(grade 4+)mitral regurgitation using the NovoClasp system.All patients had a baseline New York Heart Association functional class oflll-lIV,with 7/11 exhibiting complex mitral valve disease.All patients achieved the primary endpoints of technical and device success,with a post-operative 30-d mitral regurgitation grade reduction to 2+or lower,which was maintained at 12 months.One patient had minor bleeding and hematoma at the access site before discharge,and 2 patients were readmitted due to fast atrial fibrillation within 12 months post-discharge.No additional cases of death,adverse cerebral or cardiovascular events,or device-related complications was observed during the follow-up.Conclusion:This study suggested the potential feasibility and safety of the NovoClasp system,showing a promising technical and device success rate,along with a decrease in mitral regurgitation severity.A further pivotal study is needed to assess the procedural and long-term outcomes.

关 键 词：Mitral valve insufficiency Transcatheter edge-to-edge repair FEASIBILITY Safety 

分 类 号：R654.2[医药卫生—外科学]